MA41643B1 - Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton - Google Patents
Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de brutonInfo
- Publication number
- MA41643B1 MA41643B1 MA41643A MA41643A MA41643B1 MA 41643 B1 MA41643 B1 MA 41643B1 MA 41643 A MA41643 A MA 41643A MA 41643 A MA41643 A MA 41643A MA 41643 B1 MA41643 B1 MA 41643B1
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- pharmaceutical formulations
- bruton
- kinase inhibitor
- conditions
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des formulations pharmaceutiques d'un inhibiteur de la tyrosine kinase de bruton (btk), le 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo [3,4-d] pyrimidin-1-yl) pipéridin-1-yl) prop-2-én-1-one. L'invention concerne des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou de pathologies auto-immunes, de maladies ou de pathologies hétéro-immunes, du cancer, y compris du lymphome, et de maladies ou de pathologies inflammatoires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127717P | 2015-03-03 | 2015-03-03 | |
PCT/US2016/020467 WO2016141068A1 (fr) | 2015-03-03 | 2016-03-02 | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41643A MA41643A (fr) | 2018-01-09 |
MA41643B1 true MA41643B1 (fr) | 2024-02-29 |
Family
ID=59254075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41643A MA41643B1 (fr) | 2015-03-03 | 2016-03-02 | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR103832A1 (fr) |
MA (1) | MA41643B1 (fr) |
-
2016
- 2016-03-02 MA MA41643A patent/MA41643B1/fr unknown
- 2016-03-02 AR ARP160100550A patent/AR103832A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR103832A1 (es) | 2017-06-07 |
MA41643A (fr) | 2018-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41654B2 (fr) | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton | |
MX2021015370A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
PH12020552065A1 (en) | Ibrutinib combination therapy | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
TN2015000168A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MA38961A1 (fr) | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose | |
MA38183A1 (fr) | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase | |
MX2019008815A (es) | Sintesis de un inhibidor de tirosina quinasa de bruton. | |
PH12015502053A1 (en) | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors | |
EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
MA41643B1 (fr) | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton |